The short version of DAC fits in a sentence. The long version — which is the one that helps — is below.
This page was last updated on 2025-10-31 and is reviewed periodically as new material appears.
Downstream of growth hormone, the liver and other tissues increase production of insulin-like growth factor 1, a mediator of many growth-promoting effects. Studies have documented elevated levels of both hormones after dosing, and the rise from the long-acting form persists longer than that produced by shorter-acting analogues. What remains unclear is whether sustained elevation of these markers translates into meaningful clinical benefit, and whether prolonged exposure carries risks that short trials could not detect.
CJC-1295 acts at the growth hormone-releasing hormone receptor, a G-protein-coupled receptor found on somatotroph cells in the anterior pituitary. Binding triggers a rise in cyclic AMP and calcium entry, which promotes release of stored growth hormone. Because the peptide mimics the body's own releasing hormone, it amplifies existing secretory pulses rather than driving continuous output. The size of the response therefore depends partly on the subject's own hormonal rhythm and feedback state.
Two forms circulate in research settings and are frequently confused. One carries the drug affinity complex and is often written as CJC-1295 with DAC; the other lacks that group and is usually called modified GRF(1-29). The two share the same core sequence but differ sharply in how long they persist in blood. Products labelled only as CJC-1295 normally refer to the version carrying the complex. Documentation that omits the distinction leaves the intended molecule ambiguous.
CJC-1295 is a synthetic peptide built as a long-acting analogue of growth hormone-releasing hormone. Its backbone matches the first twenty-nine residues of the natural human hormone, with four amino acid substitutions added to slow enzymatic breakdown. A reactive maleimide group, commonly termed the drug affinity complex, allows the peptide to attach to circulating albumin after administration. That albumin attachment keeps the molecule in the bloodstream for an extended period instead of being cleared within minutes.
The compound emerged from work at a Canadian biotechnology firm in the early 2000s. Early human studies examined its effect on growth hormone and insulin-like growth factor 1 in healthy volunteers and in people with HIV-associated fat redistribution. Reports described sustained increases in both markers after a single injection. Development did not advance to regulatory approval, and the clinical programme was later discontinued. The molecule is now encountered mainly as a research chemical rather than a marketed medicine.
| Property | Value | Notes |
|---|---|---|
| Primary target | GHRH receptor | G-protein-coupled receptor on pituitary somatotrophs |
| Half-life, long-acting form | Several days | Extended by covalent albumin binding |
| Half-life, short form | About 30 minutes | Cleared rapidly by peptidases and kidneys |
| Route in studies | Subcutaneous injection | Used in the published human trials |
| Main measured effect | Rise in GH and IGF-1 | Surrogate markers rather than clinical endpoints |
Clearance profiles diverge sharply between the two versions. The albumin-binding molecule stays in plasma for several days, whereas the unmodified analog is largely gone within about half an hour in reported work. Cleavage by dipeptidyl peptidase IV is a major contributor to the short life of the unmodified sequence. These gaps mean the two versions cannot be substituted for each other in study design or in reading results side by side.
Reports on this compound commonly follow serum growth hormone and insulin-like growth factor 1 across defined time windows. Protocols differ in sampling frequency, assay platform, and participant characteristics, which makes direct comparison between publications difficult. Some work focuses on pulsatile release patterns instead of average concentrations. Whether repeated exposure alters endogenous hormone rhythms over long periods remains an open question, and the formal literature is thinner than the volume of informal commentary implies.
Once in circulation, the peptide binds the growth hormone-releasing hormone receptor displayed on pituitary somatotroph cells. Receptor activation couples to Gs proteins, elevates intracellular cyclic AMP, and drives protein kinase A signaling inside the cell. That cascade increases discharge of growth hormone into the bloodstream. The analog therefore operates through a receptor pathway that already exists for the body's own releasing hormone, rather than through an engineered artificial target.
Four amino acid substitutions separate the modified backbone from the parent GRF(1-29) sequence. These changes reduce recognition by dipeptidyl peptidase IV and related proteases, extending the interval before degradation. Development work in this area sought longer-acting GHRH analogs for endocrine investigation. Published descriptions treat the substitution set as a defining property of the core sequence, while the albumin-binding linker is described separately as an optional addition to that same backbone.
CJC-1295 is a synthetic peptide analog of growth hormone-releasing hormone, constructed on the 29-amino-acid fragment designated GRF(1-29). The name began as an internal development code during the 1990s and later spread through research supply catalogs and discussion forums. The molecule does not occur in nature; its sequence is engineered rather than isolated from tissue. Two related compounds are sold under this single label, and they differ by one appended chemical group that strongly influences how long the peptide remains in circulation.
The peptide backbone includes a D-alanine at position two, which resists cleavage by dipeptidyl peptidase IV, and several other substitutions that reduce degradation. Its molecular weight is roughly 3.4 kDa without the linker and about 3.6 kDa with it. The molecule is water soluble and is normally supplied as a lyophilized powder. Precise sequence and mass values depend on which variant is described, so technical documents usually state the exact form being referenced.
CJC-1295 is a synthetic peptide designed as a long-acting analogue of growth hormone-releasing hormone (GHRH). Its structure derives from the first 29 amino acids of native GHRH, a fragment often called GRF(1-29). Four substitutions were introduced to slow enzymatic breakdown and extend activity relative to the natural sequence. The compound was developed by ConjuChem as part of a broader effort to improve the pharmacokinetic profile of peptide hormones. It is studied in laboratory and clinical research settings rather than appearing as a naturally occurring substance.
=== Structural Biology and Protein Engineering === This program studies biomolecules using protein engineering and molecular biology techniques. Methodologies include X-ray crystallography and cryo-EM. Research includes protein structure determination and mass spectrometry methods.
These variables (S, I, and R) represent the number of people in each compartment at a particular time. To represent that the number of susceptible, infectious, and removed individuals may vary over time (even if the total population size remains constant), we make the precise numbers a function of t (time): S(t), I(t), and R(t). For a specific disease in a specific population, these functions may be worked out in order to predict possible outbreaks and bring them under control. Note that in the SIR model,
In 2004, a special issue of The International Journal of Sociology and Social Policy was published that was edited by Steven P. Schacht, who participated in the SSSP session. The special issue contained ten articles analyzing his research and his multiple contributions as a social activist and scholar. The authors of these articles call for sociologists and others to move beyond criticism of Humphrey's research methodologies in the tearoom study, and instead to focus on his pioneering contributions to the study of sexuality, participant-observation as method, development of sociological theory, and his work as a social activist and advocate for marginalized sexual identities.
After the Fermi publication, Otto Hahn, Lise Meitner, and Fritz Strassmann began performing similar experiments in Berlin. Meitner, an Austrian Jew, lost her Austrian citizenship with the Anschluss, the union of Austria with Germany in March 1938, but she fled in July 1938 to Sweden and started a correspondence by mail with Hahn in Berlin. By coincidence, her nephew Otto Robert Frisch, also a refugee, was also in Sweden when Meitner received a letter from Hahn dated 19 December describing his chemical proof that some of the product of the bombardment of uranium with neutrons was barium. Hahn suggested a bursting of the nucleus, but he was unsure of what the physical basis for the results were. Barium had an atomic mass 40% less than uranium, and no previously known methods of radioactive decay could account for such a large difference in the mass of the nucleus. Frisch was skeptical, but Meitner trusted Hahn's ability as a chemist. Marie Curie had been separating barium from radium for many years, and the techniques were well known. Meitner and Frisch then correctly interpreted Hahn's results to mean that the nucleus of uranium had split roughly in half. Frisch suggested the process be named "nuclear fission", by analogy to the process of living cell division into two cells, which was then called binary fission. Just as the term nuclear "chain reaction" would later be borrowed from chemistry, so the term "fission" was borrowed from biology.
==== Monoamine oxidase B (MAO-B) inhibitors ==== Rasagiline (Agilect; AGN-1135; Azilect; Elbrus; Lu-00-773; TV-1030; TVP-101; TVP-1012) – monoamine oxidase B (MAO-B) inhibitor [338] Safinamide (EMD-1195686; Equfina; FCE-26743; ME-2125; NW-1015; Onstryv; PNU-151774; Xadago; ZP-034) – reversible monoamine oxidase B (MAO-B) inhibitor and other actions [339] Selegiline (Eldepryl, Jumex) – monoamine oxidase B (MAO-B) inhibitor and other actions Selegiline orally disintegrating tablet (Efupi; FPF-1100-NW; selegiline ODT) – monoamine oxidase B (MAO-B) inhibitor and other actions [340]
Sources: en.wikipedia.org
Proamylin, which is cosecreted with proinsulin, requires the above three factors and an amidating monooxygenase to convert itself to an active hormone. Some pro-protein precursors, such as preproinsulin, also go through this process, with the added step of removing a signal peptide by signal peptidases, to convert said precursors into prohormones.
== Bibliography == Barkawi, Tarak (April 2006). "Culture and Combat in the Colonies: The Indian Army In the Second World War". Journal of Contemporary History. 41 (2). Sage: 325–355. doi:10.1177/0022009406062071. S2CID 145364543. Barthorp, Michael (2002). Afghan Wars and the North-West Frontier 1839–1947. London: Cassel. ISBN 0-304-36294-8. Barua, Pradeep (2003). Gentlemen of the Raj: The Indian Army Officer Corps, 1817–1949. Westport, CT: Praegar. ISBN 0275979997. Chandler, David (2002). Oxford History of the British Army (2nd ed.). USA: Oxford University Press. ISBN 0192803115. Gaylor, John (1996). Sons of John Company – The Indian & Pakistan Armies 1903–1991. Tunbridge Wells, Kent: Parapress. ISBN 1-898594-41-4. Haythornthwaite, P.J. (1992). The World War One Sourcebook. Arms and Armour Press. Heathcote, T. A. (1974). The Indian Army – The Garrison of British Imperial India, 1822–1922. Newton Abbot, Devon: David & Charles. Ilbert, Courtenay (1 January 1913). "British India". Journal of the Society of Comparative Legislation. 13 (2): 327–333. JSTOR 752287. Imperial Gazetteer of India, Volume IV (1908). Indian Empire: Administrative. Oxford: Clarendon Press. p. 552. Jackson, Donovan (1940). India's Army. London: Sampson Low. Lapping, Brian (1985). End of Empire. London: Guild Publishing. Mazumder, Rajit K. (2003). The Indian army and the making of Punjab. Delhi, India: Permanent Black. ISBN 8178240599. Nathan, R.; Lee-Warner, William; Carnduff, H. W. C.; Maclagan, E. D.; Walker, G. H. D.; Collen, Edwin; Nathan; Bythel, W. J.; Hemming, T. H. (1908).
β-carotene can be extracted from fungus Blakeslea trispora, marine algae Dunaliella salina or genetically modified yeast Saccharomyces cerevisiae, starting with xylose as a substrate. Chemical synthesis uses either a method developed by BASF or a Grignard reaction utilized by Hoffman-La Roche. The world market for synthetic retinol is primarily for animal feed, leaving approximately 13% for a combination of food, prescription medication and dietary supplement use. Industrial methods for the production of retinol rely on chemical synthesis. The first industrialized synthesis of retinol was achieved by the company Hoffmann-La Roche in 1947. In the following decades, eight other companies developed their own processes. β-ionone, synthesized from acetone, is the essential starting point for all industrial syntheses. Each process involves elongating the unsaturated carbon chain. Pure retinol is extremely sensitive to oxidization and is prepared and transported at low temperatures and oxygen-free atmospheres. When prepared as a dietary supplement or food additive, retinol is stabilized as the ester derivatives retinyl acetate or retinyl palmitate. Prior to 1999, three companies, Roche, BASF and Rhone-Poulenc controlled 96% of global vitamin A sales. In 2001, the European Commission imposed total fines of 855.22 million euros on these and five other companies for their participation in eight distinct market-sharing and price-fixing cartels that dated back to 1989. Roche sold its vitamin division to DSM in 2003. DSM and BASF have the major share of industrial production.
== Discovery == URP was discovered in rats when researchers were trying to locate urotensin II (UII), a neuropeptide that is a potent vasoconstrictor and increases REM cycles in the brain. The researchers designed antibodies using Goby UII as an antigen that would target the specific peptide sequence CFWKYC. When the peptide was observed using a mass spectrometer the scientists discovered this peptide was smaller than UII but had similar characteristics as well which is why it was called Urotensin II-related peptide.
Sources: en.wikipedia.org
It binds the growth hormone-releasing hormone receptor on pituitary somatotroph cells. Receptor activation raises cyclic AMP and promotes release of stored growth hormone granules. Because the peptide persists longer than natural releasing hormone, stimulation is prolonged rather than brief.
The drug affinity complex links the peptide to serum albumin through a covalent bond. The conjugate is too large to be filtered quickly by the kidneys and is shielded from enzymatic breakdown. This extends the apparent half-life from roughly minutes to several days.
Long-term safety and any clinical benefit are unestablished. Published human data cover small groups over limited periods and focus on hormone levels rather than health outcomes. Whether prolonged elevation of growth hormone and insulin-like growth factor 1 is beneficial or harmful is an open question.
It is a synthetic peptide analogue of growth hormone-releasing hormone. Four substitutions in its sequence make it more resistant to enzymatic degradation than the natural hormone. In the version carrying a drug affinity complex, the peptide binds albumin and remains in circulation for days.